In this episode, 2 European HIV experts share their thoughts on some of the most important new antiretroviral therapy insights from HIV research over the past year.Specifically, the faculty discuss findings from real-world and long-term studies of 2-drug oral regimens, the latest on 2-drug long-acting injectable therapy, how 2-drug options fit into rapid start strategies, and other new and emerging innovations in HIV treatment, including the availability of lenacapavir for multidrug-resistant HIV treatment and resumption of islatravir clinical development.Presenters:Jürgen K. Rockstroh, MDProfessor of MedicineUniversity Hospital BonnDepartment of Medicine IBonn, GermanyAlexandra Calmy, MD, FMH, PhDHIV/AIDS Unit DirectorInfectious Diseases DivisionGeneva University HospitalsUniversity of GenevaGeneva, SwitzerlandContent based on an online program supported by an independent educational grant from Gilead Sciences, Inc. andViiV Healthcare.Link to full program:http://bit.ly/3Hz0jNa